首页> 外文期刊>Drug Metabolism and Disposition: The Biological Fate of Chemicals >Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy.
【24h】

Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy.

机译:17β-雌二醇上调UDP-葡萄糖醛酸转移酶(UGT)1A4:在妊娠期增加拉莫三嗪消除的潜在机制。

获取原文
获取原文并翻译 | 示例
           

摘要

Oral clearance of lamotrigine, an antiepileptic drug commonly used in pregnant women, is increased in pregnancy by unknown mechanisms. In this study, we show that 17beta-estradiol (E(2)) up-regulates expression of UDP glucuronosyltransferase (UGT) 1A4, the major enzyme responsible for elimination of lamotrigine. Endogenous mRNA expression levels of UGT1A4 in estrogen receptor (ER) alpha-negative HepG2 cells were induced 2.3-fold by E(2) treatment in the presence of ER alpha expression. E(2) enhanced transcriptional activity of UGT1A4 in a concentration-dependent manner in HepG2 cells when ER alpha was cotransfected. Induction of UGT1A4 transcriptional activity by E(2) was also observed in ER alpha-positive MCF7 cells, which was abrogated by pretreatment with the antiestrogen fulvestrant (ICI 182,780). Analysis of UGT1A4 upstream regions using luciferase reporter assays identified a putative specificity protein-1 (Sp1) binding site (-1906 to -1901 base pairs) that is critical for the induction of UGT1A4 transcriptional activity by E(2). Deletion of the Sp1 binding sequence abolished the UGT1A4 up-regulation by E(2), and Sp1 bound to the putative Sp1 binding site as determined by a electrophoretic mobility shift assay. Analysis of ER alpha domains using ER alpha mutants revealed that the activation function (AF) 1 and AF2 domains but not the DNA binding domain of ER alpha are required for UGT1A4 induction by E(2) in HepG2 cells. Finally, E(2) treatment increased lamotrigine glucuronidation in ER alpha-transfected HepG2 cells. Together, our data indicate that up-regulation of UGT1A4 expression by E(2) is mediated by both ER alpha and Sp1 and is a potential mechanism contributing to the enhanced elimination of lamotrigine in pregnancy.
机译:拉莫三嗪是孕妇常用的抗癫痫药,其口服清除率在孕期因未知机制而增加。在这项研究中,我们表明17β-雌二醇(E(2))上调UDP葡萄糖醛糖基转移酶(UGT)1A4(负责消除拉莫三嗪的主要酶)的表达。雌激素受体(ER)阴性的HepG2细胞中UGT1A4的内源性mRNA表达水平在存在ERα表达的情况下通过E(2)处理诱导2.3倍。当ERα被共转染时,E(2)以浓度依赖性的方式增强了UGT1A4在HepG2细胞中的转录活性。在ERα阳性的MCF7细胞中也观察到了E(2)对UGT1A4转录活性的诱导,该抗细胞通过用抗雌激素富氟司亭进行预处理而被废除(ICI 182,780)。使用荧光素酶报告基因分析对UGT1A4上游区域进行分析,确定了推定的特异性蛋白-1(Sp1)结合位点(-1906至-1901个碱基对),该位点对于E(2)诱导UGT1A4转录活性至关重要。 Sp1结合序列的删除取消了E(2)的UGT1A4上调,并且Sp1结合了假定的Sp1结合位点,如通过电泳迁移率变动分析所确定。使用ER alpha突变体对ER alpha域的分析显示,激活功能(AF)1和AF2域,而不是ER alpha的DNA结合域,是HepG2细胞中E(2)诱导UGT1A4所必需的。最后,E(2)治疗增加了ERα转染的HepG2细胞中的拉莫三嗪葡萄糖醛酸苷化。在一起,我们的数据表明,由E(2)对UGT1A4表达的上调是由ER alpha和Sp1介导的,并且是促进妊娠期拉莫三嗪消除的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号